GENinCode UK Ltd. (GENI) AI Stock Analysis

• Market Cap: £4.02M
• Dividend Yield: N/A
• Average Volume (3M): 377.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: 25.05%
• EPS Growth: 65.30%
• Country: UK
• Employees: 42
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 286,882,050
• 10 Day Avg. Volume: 258,330
• 30 Day Avg. Volume: 377,976
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £1.50
• Price Target Upside: 7.14% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: 1.50p ▲(7.14% Upside)

GENinCode UK Ltd. faces significant financial challenges, with persistent losses and cash flow issues being the most critical factors. The technical analysis suggests a bearish trend, while the valuation is hampered by negative earnings. However, recent corporate events show positive strategic developments, which could support future growth.

GENinCode UK Ltd. Business Overview & Revenue Model

Company Description

GENinCode UK Ltd. (GENI) is a healthcare company that specializes in the development and commercialization of genetic risk assessment tests for cardiovascular diseases. The company operates within the biotechnology and healthcare sectors, focusing on predictive genetics and precision medicine. GENinCode's core product offerings include a suite of advanced genetic tests designed to evaluate an individual's risk of developing cardiovascular conditions, thereby enabling personalized preventative strategies and interventions.

How the Company Makes Money

GENinCode UK Ltd. generates revenue through the sale of its proprietary genetic testing services. The company's key revenue streams include direct sales of genetic tests to healthcare providers, clinics, and hospitals, as well as partnerships with medical institutions and research organizations. GENinCode may also generate income through collaborations with pharmaceutical companies seeking to integrate genetic risk assessments into clinical trials and drug development processes. Additionally, the company might engage in licensing agreements for its technology and intellectual property with other entities in the healthcare and biotechnology sectors.

GENinCode UK Ltd. Financial Statement Overview

Summary

GENinCode UK Ltd. is facing ongoing financial challenges, characterized by persistent losses and cash flow constraints. While revenue growth is a positive sign, the company's inability to achieve profitability, coupled with declining equity and reliance on external financing, highlights significant risks.

Income Statement

The income statement reveals persistent challenges, with a series of net losses despite a steady increase in revenue from 2020 to 2024. The gross profit margin has shown improvement, but the net profit margin remains negative due to significant operating losses as evidenced by negative EBIT and EBITDA margins. The company is working on expanding its revenue base; however, profitability remains a challenge.

Balance Sheet

The balance sheet shows a decline in stockholders' equity over the years, with a negative equity encountered in 2019. While the company has maintained low levels of debt, the equity ratio has decreased significantly, indicating financial vulnerability. The return on equity is negative, reflecting ongoing losses.

Cash Flow

Cash flow analysis points to significant negative operating cash flows, indicating challenges in generating cash from operations. Although there has been improvement in free cash flow over the recent period, the overall trend remains negative. The company relies heavily on financing activities to support operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.70M	2.16M	1.43M	1.15M	960.80K
Gross Profit	1.43M	1.02M	632.00K	593.00K	523.02K
EBITDA	-4.69M	-6.65M	-5.57M	-4.10M	-1.03M
Net Income	-4.43M	-7.02M	-5.56M	-4.14M	-1.07M
Balance Sheet
Total Assets	2.66M	4.19M	11.80M	15.21M	2.42M
Cash, Cash Equivalents and Short-Term Investments	1.17M	2.53M	9.75M	14.56M	2.00M
Total Debt	234.00K	299.00K	354.00K	0.00	0.00
Total Liabilities	1.54M	2.90M	3.90M	1.49M	563.50K
Stockholders Equity	1.13M	1.29M	7.90M	13.72M	1.86M
Cash Flow
Free Cash Flow	-5.22M	-7.54M	-4.61M	-3.17M	-1.11M
Operating Cash Flow	-5.17M	-7.51M	-3.76M	-3.02M	-1.04M
Investing Cash Flow	50.00K	136.00K	-849.00K	-145.00K	-68.27K
Financing Cash Flow	3.65M	-94.00K	-47.00K	15.86M	3.03M

GENinCode UK Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.54, below the 50-day MA of 1.82, and below the 200-day MA of 2.80, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 23.07 is Positive, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENI.

GENinCode UK Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
GDR	51 Neutral	£4.84M	―	-321.90%	―	125.37%	22.47%
GENI	46 Neutral	£4.02M	―	-367.05%	―	25.05%	65.30%
CNSL	―	£7.73M	4.92	14.85%	―	―	―
ABDX	59 Neutral	£11.62M	―	-62.83%	―	27.60%	1.35%
VRCI	45 Neutral	£7.95M	―	-130.73%	―	226.45%	53.51%
PRM	41 Neutral	£8.86M	―		―	-2.80%	-38.55%

GENinCode UK Ltd. Corporate Events

GENinCode Updates on FDA De Novo Submission Progress

GENinCode Plc announced an update on its FDA De Novo submission, revealing that while the number of outstanding deficiencies has decreased, further information related to clinical validation is still required. The company remains optimistic about addressing these deficiencies through ongoing discussions with the FDA, although there is no certainty that the information provided will be sufficient for approval.

GENinCode Plc Successfully Passes All Resolutions at AGM

GENinCode Plc announced that all resolutions were passed at their Annual General Meeting held in Oxford, UK. This development underscores the company’s continued focus on advancing its predictive genetics technology in the prevention of cardiovascular disease and ovarian cancer, potentially strengthening its market position and stakeholder confidence.

GENinCode Plc Reports 25% Revenue Growth and Expands US Market Presence

GENinCode Plc reported a 25% increase in revenues for FY24, driven by growth in the UK and Europe, and introduced its polygenic tests to the US market. The company received its first US test revenues for its LIPID inCode and CARDIO inCode products, with the latter receiving a US Notice of Allowance for patent status. The NHS expanded the use of LIPID inCode for familial hypercholesterolemia diagnosis, and the CARDIO inCode pilot was launched in Spain. The company also completed a £4.1m secondary placing to support its scale-up and commercialization efforts. For FY25, GENinCode aims to significantly increase revenues, improve margins, and move towards breakeven, with plans for commercial expansion in the US and further development of its NHS and EU programs.

GENinCode Announces Release Date for 2024 Financial Results

GENinCode Plc has announced it will release its audited final results for the year ending December 2024 on June 4, 2025. The company will hold a briefing for equity research analysts and a live investor presentation to discuss the results. This announcement is significant as it reflects GENinCode’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.